ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

SEGMENT REPORTING (Tables)

6 Months Ended

Jun. 30, 2026


		Three Months Ended June 30,					Six Months Ended June 30,
		2026			2025		2026			2025
Operating Expenses:
PMN310 development program costs		$	7,785,427		$	8,050,610	$	14,049,539		$	12,776,951
Other non-employee research and development costs			310,571			220,669		503,285			498,584
Employee costs			2,916,715			1,053,258		4,030,478			2,496,325
Other general and administrative costs			1,253,686			860,124		2,327,994			1,872,897
Net Operating Loss:		$	12,266,399		$	10,184,661	$	20,911,296		$	17,644,757
Other income			(536,743)			(67,632)		(937,267)			(179,825)
Net Loss:		$	11,729,656		$	10,117,029	$	19,974,029		$	17,464,932

Reconciliation of Loss
Adjustments and reconciling items			—			—		—			—
Consolidated Net Loss:		$	11,729,656		$	10,117,029	$	19,974,029		$	17,464,932